Structure Therapeutics reported mid-stage results showing its oral GLP-1 candidate aleniglipron produced an average ~16% body-weight reduction at 44 weeks, a magnitude that approaches injectable GLP-1 standards. The Phase 2 data were presented by the company and framed as justification for moving into pivotal testing later this year. The trial used a step-up dosing regimen to manage tolerability and reported fewer discontinuations than earlier datasets, according to company disclosures. Analysts immediately compared the outcome to rival oral and injectable GLP-1 programs, citing potential competitive pressure on market incumbents. Structure said it will advance aleniglipron into Phase 3 planning based on these efficacy and tolerability signals. Regulators and payers will likely scrutinize safety and long-term durability; the company plans additional readouts and regulatory engagement ahead of a pivotal program.